Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Biostar’s Q1 Revenues Rise 9%

publication date: May 28, 2009

Biostar Pharmaceuticals reported Q1 revenues climbed 9% to $7.4 million, while net income remained flat at $1.8 million. Earnings per share were 8 cents. The company said sales improved in four of its five SFDA approved drugs, a result of its initiative to market directly to rural consumers through retail pharmacies. The push to increase retail sales increased SG&A costs from 30% of revenues to 33%. That was enough to keep net income from rising in concert with total revenues. More details...

Stock Symbol: (OTCBB: BSPM)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital